SMMT Stock Heads For Third Straight Weekly Drop – Analyst Tempers Expectations From Initial Lung Cancer Trial Survival Data

SMMT stock is heading for a third straight weekly drop.

Analysts are tempering expectations from initial survival data of an early-stage lung cancer trial.

Enrollment is complete in both squamous and non-squamous cohorts of the Harmoni-3 trial for metastatic non-small cell lung cancer.